ORGO Organogenesis Inc.: Net earnings per one share for the last twelve months

The TTM annual net income per share growth rate for Organogenesis Holdings (ORGO) shows that the current parameter is -1169.50. This correlates with the implementation of automated bioreactors for tissue engineering. Stability is further confirmed by compliance with ESG environmental standards regarding waste disposal. Organogenesis Holdings (ORGO) maintains its leadership in regenerative medicine through the creation of unique skin substitutes that have become the industry standard in surgery.
ORGO (Organogenesis): analytical breakdowns and indicator data

The dynamics of this indicator reflect the sensitivity of net earnings per share to operational efficiency, measuring the annual change in yield over a rolling twelve-month period to assess the market control premium. Organogenesis Holdings (ORGO) reducing its dependence on Medicare tariffs through the diversification of biomaterial sales directly impacts the metric's calculation logic, as clearly demonstrated by the current EPS YoY TTM growth rate.